Bo Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Bo Liu has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
Wen Pan
Emergency Department of Beijing You'an Hospital, Capital Medical University
6 shared publicationsZhao Liu
Emergency Department of Beijing You'an Hospital, Capital Medical University
6 shared publicationsHongbo Shi
Beijing Institute of Hepatology, Beijing Youan Hospital, Capital Medical University, Beijing, People’s Republic of China
4 shared publicationsNan Geng
Emergency Department of Beijing You'an Hospital, Capital Medical University
4 shared publications- Yingmin Ma
Department of Respiratory and Critical Care Medicine, Beijing Youan Hospital, Capital Medical University, Beijing, China
4 shared publications - Nan Geng
Department of Emergency Medicine, Beijing Youan Hospital, Capital Medical University, Beijing, 100069, People’s Republic of China
3 shared publications
Latest Publications
- Open Access
- 9 September 2026
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 13, 1761466
The prognostic value of DIC score combined with lactate in patients with cirrhosis complicated by variceal upper gastrointestinal bleeding: a single-center retrospective cohort study
Objective: This study aimed to investigate the predictive value of the disseminated intravascular coagulation (DIC) score combined with lactate (Lac) for the prognosis of patients with cirrhosis and variceal upper gastrointestinal bleeding (VUGIB). Methods: In this retrospective cohort study, we enrolled 409 patients with liver cirrhosis and VUGIB who were admitted to Beijing You'an Hospital, Capital Medical University, between July 2023 and July 2025.The predictive outcomes were 28-day mortality, multiple organ dysfunction syndrome (MODS), and admission to the intensive care unit (ICU). Univariate baseline comparisons were performed. A multivariable logistic primary model was constructed, and two types of sensitivity analyses were established. The independence of the DIC score as a prognostic factor was assessed using Wald, likelihood-ratio, and interaction tests. Receiver operating characteristic (ROC) curves were plotted, and the areas under the curves (AUCs) of the models were compared using DeLong's test. Internal validation was conducted with 1,000 bootstrap resamples. Model calibration was evaluated using the Hosmer-Lemeshow test and calibration curves. The optimal cut-off value was determined via 10-fold cross-validation, and survival differences were analyzed using the Kaplan–Meier method. Decision curve analysis was performed to evaluate the net clinical benefit. Results: Univariate analysis revealed that lactate, DIC score, and various liver function and bleeding scores differed significantly among the three prognostic outcome groups (all P < 0.05). After adjusting for covariates, DIC score was identified as an independent risk factor for all three outcomes, and its predictive value was independent of Child-Pugh and MELD-Na scores, with no interaction between them. ROC analysis showed that the combined lactate + DIC model had the best discriminative performance (AUC for mortality = 0.892, for MODS = 0.889, for ICU admission = 0.851), and DeLong's test confirmed that it was superior to most conventional scores. After bootstrap correction, the model exhibited no significant optimism bias, and the Hosmer-Lemeshow test indicated good calibration. Stratification by the cross-validation-derived cutoff value revealed statistically significant differences in 28-day survival between high-and low-risk patients across all outcome groups (log-rank P < 0.001). Decision curve analysis demonstrated that the lactate + DIC model provided higher net clinical benefit than DIC score alone. Conclusion: The combination of DIC score and lactate independently predicts the risks of 28-day mortality, MODS, and ICU admission in patients with liver cirrhosis and VUGIB. Multidimensional validation demonstrated that this model exhibited superior discrimination, calibration, and net clinical benefit compared with any single score, and thus can be applied for early risk stratification at admission.
- 9 September 2026
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 13, 1761466
Open AccessThe prognostic value of DIC score combined with lactate in patients with cirrhosis complicated by variceal upper gastrointestinal bleeding: a single-center retrospective cohort study
Objective: This study aimed to investigate the predictive value of the disseminated intravascular coagulation (DIC) score combined with lactate (Lac) for the prognosis of patients with cirrhosis and variceal upper gastrointestinal bleeding (VUGIB). Methods: In this retrospective cohort study, we enrolled 409 patients with liver cirrhosis and VUGIB who were admitted to Beijing You'an Hospital, Capital Medical University, between July 2023 and July 2025.The predictive outcomes were 28-day mortality, multiple organ dysfunction syndrome (MODS), and admission to the intensive care unit (ICU). Univariate baseline comparisons were performed. A multivariable logistic primary model was constructed, and two types of sensitivity analyses were established. The independence of the DIC score as a prognostic factor was assessed using Wald, likelihood-ratio, and interaction tests. Receiver operating characteristic (ROC) curves were plotted, and the areas under the curves (AUCs) of the models were compared using DeLong's test. Internal validation was conducted with 1,000 bootstrap resamples. Model calibration was evaluated using the Hosmer-Lemeshow test and calibration curves. The optimal cut-off value was determined via 10-fold cross-validation, and survival differences were analyzed using the Kaplan–Meier method. Decision curve analysis was performed to evaluate the net clinical benefit. Results: Univariate analysis revealed that lactate, DIC score, and various liver function and bleeding scores differed significantly among the three prognostic outcome groups (all P < 0.05). After adjusting for covariates, DIC score was identified as an independent risk factor for all three outcomes, and its predictive value was independent of Child-Pugh and MELD-Na scores, with no interaction between them. ROC analysis showed that the combined lactate + DIC model had the best discriminative performance (AUC for mortality = 0.892, for MODS = 0.889, for ICU admission = 0.851), and DeLong's test confirmed that it was superior to most conventional scores. After bootstrap correction, the model exhibited no significant optimism bias, and the Hosmer-Lemeshow test indicated good calibration. Stratification by the cross-validation-derived cutoff value revealed statistically significant differences in 28-day survival between high-and low-risk patients across all outcome groups (log-rank P < 0.001). Decision curve analysis demonstrated that the lactate + DIC model provided higher net clinical benefit than DIC score alone. Conclusion: The combination of DIC score and lactate independently predicts the risks of 28-day mortality, MODS, and ICU admission in patients with liver cirrhosis and VUGIB. Multidimensional validation demonstrated that this model exhibited superior discrimination, calibration, and net clinical benefit compared with any single score, and thus can be applied for early risk stratification at admission.
- Open Access
- 13 May 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1749708
Prognostic significance of lymphocyte PD-1 expression in combination with clinical scoring systems in patients with liver cirrhosis complicated by sepsis
Background: Liver cirrhosis complicated by sepsis is associated with significant immune dysfunction and high mortality rates. Programmed cell death protein 1 (PD-1) expression on lymphocytes has been implicated in immune exhaustion, but its prognostic significance in this population remains unclear. Objective: This study aimed to evaluate the prognostic value of lymphocyte PD-1 expression in combination with clinical scoring systems, such as the Child-Pugh score and chronic liver failure-sequential organ failure assessment (CLIF-SOFA), for predicting disease severity and 28-day mortality in patients with cirrhosis complicated by sepsis. Methods: This prospective study included 86 patients with cirrhosis and sepsis admitted to Beijing You’an Hospital between June 2023 and May 1, 2024. Fresh whole blood was collected at enrollment, and peripheral blood mononuclear cells (PBMCs) were isolated for flow cytometric analysis of PD-1 expression on CD3+, CD4+, and CD8+ lymphocytes. Clinical parameters, scoring systems, and laboratory data were collected to assess their correlation with PD-1 expression and patient outcomes. Results: Of the 86 patients, 38 (44.2%) survived, while 48 (55.8%) died within 28 days. Non-survivors exhibited higher PD-1 expression on CD3+, CD4+, and CD8+ lymphocytes, as well as worse Child-Pugh and CLIF-SOFA scores (all p < 0.05). A significant positive correlation was observed between lymphocyte PD-1 expression and disease severity scores. Multivariate logistic regression analysis identified PD-1 expression on CD3+, CD4+, and CD8+ lymphocytes as independent predictors of 28-day mortality. Combining lymphocyte PD-1 expression with clinical scoring systems improved the predictive accuracy for septic shock and mortality. Conclusion: Lymphocyte PD-1 expression is associated with disease severity and poor prognosis in patients with cirrhosis complicated by sepsis. Combining PD-1 expression with traditional scoring systems enhances risk stratification and may provide a more comprehensive tool for predicting outcomes in this high-risk population.
- 13 May 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1749708
Open AccessPrognostic significance of lymphocyte PD-1 expression in combination with clinical scoring systems in patients with liver cirrhosis complicated by sepsis
Background: Liver cirrhosis complicated by sepsis is associated with significant immune dysfunction and high mortality rates. Programmed cell death protein 1 (PD-1) expression on lymphocytes has been implicated in immune exhaustion, but its prognostic significance in this population remains unclear. Objective: This study aimed to evaluate the prognostic value of lymphocyte PD-1 expression in combination with clinical scoring systems, such as the Child-Pugh score and chronic liver failure-sequential organ failure assessment (CLIF-SOFA), for predicting disease severity and 28-day mortality in patients with cirrhosis complicated by sepsis. Methods: This prospective study included 86 patients with cirrhosis and sepsis admitted to Beijing You’an Hospital between June 2023 and May 1, 2024. Fresh whole blood was collected at enrollment, and peripheral blood mononuclear cells (PBMCs) were isolated for flow cytometric analysis of PD-1 expression on CD3+, CD4+, and CD8+ lymphocytes. Clinical parameters, scoring systems, and laboratory data were collected to assess their correlation with PD-1 expression and patient outcomes. Results: Of the 86 patients, 38 (44.2%) survived, while 48 (55.8%) died within 28 days. Non-survivors exhibited higher PD-1 expression on CD3+, CD4+, and CD8+ lymphocytes, as well as worse Child-Pugh and CLIF-SOFA scores (all p < 0.05). A significant positive correlation was observed between lymphocyte PD-1 expression and disease severity scores. Multivariate logistic regression analysis identified PD-1 expression on CD3+, CD4+, and CD8+ lymphocytes as independent predictors of 28-day mortality. Combining lymphocyte PD-1 expression with clinical scoring systems improved the predictive accuracy for septic shock and mortality. Conclusion: Lymphocyte PD-1 expression is associated with disease severity and poor prognosis in patients with cirrhosis complicated by sepsis. Combining PD-1 expression with traditional scoring systems enhances risk stratification and may provide a more comprehensive tool for predicting outcomes in this high-risk population.
- Open Access
- 1 March 2026
- Published by Taylor & Francis in International Journal of General Medicine
- Vol. ume 19, 1-13
Predictive Value of the Combination of Lactate and qSOFA Score for Clinical Outcomes in Cirrhotic Patients with Esophagogastric Variceal Bleeding
The objective of our research was to examine the predictive power of the combination of lactate and the quick Sepsis-Related Organ Failure Assessment (qSOFA) score on clinical outcomes in cirrhotic patients with EGVB. This single-center retrospective study consecutively enrolled 547 eligible cirrhotic patients with EGVB admitted to the Emergency Department of Beijing You’an Hospital between July 2022 and November 2022. Data collected included Lactate levels, qSOFA, pre-endoscopic Rockall score (pRS), Glasgow-Blatchford score (GBS), albumin, international normalized ratio (INR), altered mental status, systolic blood pressure, age older than 65 years score (AIMS65), and age, blood tests, comorbidities scores (ABC). These variables were used to predict rebleeding, ICU-admission, and 6-week mortality. Receiver operating characteristic (ROC) curves and logistic regression analysis were used to assess the prognostic value of the scoring systems. Lactate and qSOFA independently predicted ICU admission and 6-week mortality (P<0.05). qSOFA alone was an independent predictor of rebleeding, but lactate was not. For rebleeding prediction, the AUC values were: pRS 0.540, GBS 0.582, AIMS65 0.519, ABC 0.510, and Lac+qSOFA 0.564. For ICU-admission, the AUC values were: pRS 0.723, GBS 0.623, AIMS65 0.787, ABC 0.760, and Lac+qSOFA 0.808. For 6-week mortality, the AUC values were: pRS 0.759, GBS 0.715, AIMS65 0.817, ABC 0.834, and Lac+qSOFA 0.818. The combination of lactate and qSOFA showed better predictive performance for ICU admission and 6-week mortality than for rebleeding. Although the combination of lactate and qSOFA offers limited utility for predicting rebleeding, it is a robust predictor of ICU admission and 6-week mortality in cirrhotic patients with EGVB. Its simplicity and rapid availability make it a highly practical tool for emergency triage in this high-risk population.
- 1 March 2026
- Published by Taylor & Francis in International Journal of General Medicine
- Vol. ume 19, 1-13
Open AccessPredictive Value of the Combination of Lactate and qSOFA Score for Clinical Outcomes in Cirrhotic Patients with Esophagogastric Variceal Bleeding
The objective of our research was to examine the predictive power of the combination of lactate and the quick Sepsis-Related Organ Failure Assessment (qSOFA) score on clinical outcomes in cirrhotic patients with EGVB. This single-center retrospective study consecutively enrolled 547 eligible cirrhotic patients with EGVB admitted to the Emergency Department of Beijing You’an Hospital between July 2022 and November 2022. Data collected included Lactate levels, qSOFA, pre-endoscopic Rockall score (pRS), Glasgow-Blatchford score (GBS), albumin, international normalized ratio (INR), altered mental status, systolic blood pressure, age older than 65 years score (AIMS65), and age, blood tests, comorbidities scores (ABC). These variables were used to predict rebleeding, ICU-admission, and 6-week mortality. Receiver operating characteristic (ROC) curves and logistic regression analysis were used to assess the prognostic value of the scoring systems. Lactate and qSOFA independently predicted ICU admission and 6-week mortality (P<0.05). qSOFA alone was an independent predictor of rebleeding, but lactate was not. For rebleeding prediction, the AUC values were: pRS 0.540, GBS 0.582, AIMS65 0.519, ABC 0.510, and Lac+qSOFA 0.564. For ICU-admission, the AUC values were: pRS 0.723, GBS 0.623, AIMS65 0.787, ABC 0.760, and Lac+qSOFA 0.808. For 6-week mortality, the AUC values were: pRS 0.759, GBS 0.715, AIMS65 0.817, ABC 0.834, and Lac+qSOFA 0.818. The combination of lactate and qSOFA showed better predictive performance for ICU admission and 6-week mortality than for rebleeding. Although the combination of lactate and qSOFA offers limited utility for predicting rebleeding, it is a robust predictor of ICU admission and 6-week mortality in cirrhotic patients with EGVB. Its simplicity and rapid availability make it a highly practical tool for emergency triage in this high-risk population.
- Open Access
- 1 January 2026
- Published by Taylor & Francis in Journal of Inflammation Research
- Vol. ume 19, 1-14
Narrative Review: Research Progress and Future Directions of Presepsin in Neurological Prognostication of Adult Post-Return of Spontaneous Circulation (Post-ROSC) Cardiac Arrest Survivors
The assessment of neurological prognosis in patients after return of spontaneous circulation (ROSC) following cardiopulmonary resuscitation (CPR) is a critical challenge in critical care medicine. Current prognostic tools (eg, clinical scales, imaging, or traditional biomarkers) have limitations in early accuracy and specificity, leading to uncertainties in treatment decision-making and prognostic communication. Presepsin (soluble CD14 subtype), an emerging inflammation- and infection-related biomarker, has gained increasing attention due to its potential association with post-CPR neurological injury and functional recovery. To address the lack of a systematic synthesis of evidence in this field, this narrative review aims to summarize the biological characteristics of presepsin, its role in neurological prognostic assessment post-CPR, and the underlying mechanisms linking presepsin to neuroinflammation and brain injury. We conducted a narrative synthesis of clinical studies retrieved from PubMed, Embase, and Cochrane Library up to (December 2025, focusing on studies correlating presepsin levels with validated neurological outcome scales. Core findings from synthesized evidence indicate that elevated presepsin levels, particularly within 24–72 hours after return of ROSC, show a consistent and significant association with poor neurological outcome (Cerebral Performance Category (CPC) 3–5) and higher mortality, and presepsin may serve as an independent prognostic factor complementary to existing tools. Major clinical implications include presepsin’s potential utility in multimodal prognostic protocols, aiding in early and more accurate outcome prediction. However, significant research gaps persist, including a lack of large-scale, multicenter validation studies, standardized measurement timepoints, and consensus on optimal cutoff values. In conclusion, current evidence supports presepsin as a promising inflammatory biomarker for neurological prognostication after cardiac arrest (CA). Future research must prioritize prospective validation in diverse cohorts and investigate its dynamic changes to establish its definitive role in clinical decision-making.
- 1 January 2026
- Published by Taylor & Francis in Journal of Inflammation Research
- Vol. ume 19, 1-14
Open AccessNarrative Review: Research Progress and Future Directions of Presepsin in Neurological Prognostication of Adult Post-Return of Spontaneous Circulation (Post-ROSC) Cardiac Arrest Survivors
The assessment of neurological prognosis in patients after return of spontaneous circulation (ROSC) following cardiopulmonary resuscitation (CPR) is a critical challenge in critical care medicine. Current prognostic tools (eg, clinical scales, imaging, or traditional biomarkers) have limitations in early accuracy and specificity, leading to uncertainties in treatment decision-making and prognostic communication. Presepsin (soluble CD14 subtype), an emerging inflammation- and infection-related biomarker, has gained increasing attention due to its potential association with post-CPR neurological injury and functional recovery. To address the lack of a systematic synthesis of evidence in this field, this narrative review aims to summarize the biological characteristics of presepsin, its role in neurological prognostic assessment post-CPR, and the underlying mechanisms linking presepsin to neuroinflammation and brain injury. We conducted a narrative synthesis of clinical studies retrieved from PubMed, Embase, and Cochrane Library up to (December 2025, focusing on studies correlating presepsin levels with validated neurological outcome scales. Core findings from synthesized evidence indicate that elevated presepsin levels, particularly within 24–72 hours after return of ROSC, show a consistent and significant association with poor neurological outcome (Cerebral Performance Category (CPC) 3–5) and higher mortality, and presepsin may serve as an independent prognostic factor complementary to existing tools. Major clinical implications include presepsin’s potential utility in multimodal prognostic protocols, aiding in early and more accurate outcome prediction. However, significant research gaps persist, including a lack of large-scale, multicenter validation studies, standardized measurement timepoints, and consensus on optimal cutoff values. In conclusion, current evidence supports presepsin as a promising inflammatory biomarker for neurological prognostication after cardiac arrest (CA). Future research must prioritize prospective validation in diverse cohorts and investigate its dynamic changes to establish its definitive role in clinical decision-making.
- Open Access
- 29 July 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-13
Evaluating the predictive performance of PIRO score against six clinical prediction scores for COVID-19 outcomes in the emergency department
The coronavirus disease 2019 (COVID-19) pandemic has led to the development of numerous prognostic models for patient assessment. However, the potential utility of the predisposition, insult/infection, response, organ dysfunction (PIRO) score in evaluating COVID-19 severity and outcomes remains unexplored, presenting a gap in current research. A retrospective analysis was conducted on a cohort of 374 individuals diagnosed with COVID-19 who were admitted to the emergency department of Beijing Youan Hospital. Demographic data, treatment regimens, and seven prognostic scoring systems, including PIRO, were evaluated. To evaluate the models’ prognostic accuracy for 28-day mortality, area under the receiver operating characteristic (AUROC) analysis was employed. Comparative performance between scoring systems was quantified using the DeLong method for paired ROC curves. Of the 374 patients meeting inclusion criteria, 120 (32.1%) died within 28 day of hospitalization. Significant disparities were observed between survivors and non-survivors regarding age, laboratory parameters, and clinical scores. Analysis of patient distribution and mortality rates across different score ranges revealed a positive correlation between score magnitude and 28-day mortality. The PIRO score demonstrated superior prognostic capability, yielding an AUC of 0.898 (95% CI 0.866–0.929). The quick sequential organ failure assessment (qSOFA) score followed closely (AUC 0.882, 95% CI 0.849–0.914). Both critical illness risk score (COVID-GRAM) and national early warning score 2 (NEWS2) exhibited AUCs exceeding 0.85 (COVID-GRAM 0.854, 95% CI 0.812–0.895; NEWS2: 0.851, 95% CI 0.813–0.889). DeLong test analysis revealed statistically significant differences in AUC between PIRO and confusion, urea, respiration, systolic pressure, age ≥ 65 (CURB-65), pneumonia severity index (PSI), COVID-GRAM, rapid acute physiology score (RAPS), and NEWS2 (all p < 0.05). Analysis revealed the PIRO scoring system as a robust predictor of 28-day mortality among COVID-19 cases presenting to the emergency setting, offering potential refinement of risk stratification and clinical management strategies.
- 29 July 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-13
Open AccessEvaluating the predictive performance of PIRO score against six clinical prediction scores for COVID-19 outcomes in the emergency department
The coronavirus disease 2019 (COVID-19) pandemic has led to the development of numerous prognostic models for patient assessment. However, the potential utility of the predisposition, insult/infection, response, organ dysfunction (PIRO) score in evaluating COVID-19 severity and outcomes remains unexplored, presenting a gap in current research. A retrospective analysis was conducted on a cohort of 374 individuals diagnosed with COVID-19 who were admitted to the emergency department of Beijing Youan Hospital. Demographic data, treatment regimens, and seven prognostic scoring systems, including PIRO, were evaluated. To evaluate the models’ prognostic accuracy for 28-day mortality, area under the receiver operating characteristic (AUROC) analysis was employed. Comparative performance between scoring systems was quantified using the DeLong method for paired ROC curves. Of the 374 patients meeting inclusion criteria, 120 (32.1%) died within 28 day of hospitalization. Significant disparities were observed between survivors and non-survivors regarding age, laboratory parameters, and clinical scores. Analysis of patient distribution and mortality rates across different score ranges revealed a positive correlation between score magnitude and 28-day mortality. The PIRO score demonstrated superior prognostic capability, yielding an AUC of 0.898 (95% CI 0.866–0.929). The quick sequential organ failure assessment (qSOFA) score followed closely (AUC 0.882, 95% CI 0.849–0.914). Both critical illness risk score (COVID-GRAM) and national early warning score 2 (NEWS2) exhibited AUCs exceeding 0.85 (COVID-GRAM 0.854, 95% CI 0.812–0.895; NEWS2: 0.851, 95% CI 0.813–0.889). DeLong test analysis revealed statistically significant differences in AUC between PIRO and confusion, urea, respiration, systolic pressure, age ≥ 65 (CURB-65), pneumonia severity index (PSI), COVID-GRAM, rapid acute physiology score (RAPS), and NEWS2 (all p < 0.05). Analysis revealed the PIRO scoring system as a robust predictor of 28-day mortality among COVID-19 cases presenting to the emergency setting, offering potential refinement of risk stratification and clinical management strategies.
- Open Access
- 1 March 2025
- Published by Taylor & Francis in Journal of Inflammation Research
- Vol. ume 18, 3511-3522
The Predictive Value of Soluble Fms-Like Tyrosine Kinase-1 for Prognosis in COVID-19 Patients
Background: Coronavirus Disease 2019 (COVID-19), caused by the novel coronavirus, has posed a significant threat to global public health, leading to substantial morbidity, mortality, and strain on healthcare resources. Despite the availability of vaccines and treatments, effective biomarkers for predicting disease progression remain limited. This study aimed to investigate the prognostic value of soluble fms-like tyrosine kinase-1 (sFlt-1) in COVID-19 patients. Methods: A prospective cohort study was conducted involving 154 COVID-19 patients, with comprehensive clinical data and laboratory parameters analyzed to evaluate the effectiveness of sFlt-1 in determining disease severity and prognosis. Results: The results revealed that sFlt-1 levels correlated significantly with disease severity, showing higher levels in severe/critical cases compared to mild cases (P< 0.05). In the deceased group, sFlt-1 levels were notably higher compared to survivors, with an area under the curve (AUC) of 0.840, showing good predictive power for 28-day mortality. Multivariable logistic regression identified sFlt-1, respiratory rate, and albumin as independent prognostic factors, with a combined AUC of 0.938 (95% CI: 0.886– 0.991) for predicting mortality risk. Conclusion: These findings underscore the potential of sFlt-1 as a valuable biomarker for clinical decision-making in managing COVID-19 patients. Future studies should focus on the clinical application of sFlt-1 and explore its underlying mechanisms to enhance patient management strategies.
- 1 March 2025
- Published by Taylor & Francis in Journal of Inflammation Research
- Vol. ume 18, 3511-3522
Open AccessThe Predictive Value of Soluble Fms-Like Tyrosine Kinase-1 for Prognosis in COVID-19 Patients
Background: Coronavirus Disease 2019 (COVID-19), caused by the novel coronavirus, has posed a significant threat to global public health, leading to substantial morbidity, mortality, and strain on healthcare resources. Despite the availability of vaccines and treatments, effective biomarkers for predicting disease progression remain limited. This study aimed to investigate the prognostic value of soluble fms-like tyrosine kinase-1 (sFlt-1) in COVID-19 patients. Methods: A prospective cohort study was conducted involving 154 COVID-19 patients, with comprehensive clinical data and laboratory parameters analyzed to evaluate the effectiveness of sFlt-1 in determining disease severity and prognosis. Results: The results revealed that sFlt-1 levels correlated significantly with disease severity, showing higher levels in severe/critical cases compared to mild cases (P< 0.05). In the deceased group, sFlt-1 levels were notably higher compared to survivors, with an area under the curve (AUC) of 0.840, showing good predictive power for 28-day mortality. Multivariable logistic regression identified sFlt-1, respiratory rate, and albumin as independent prognostic factors, with a combined AUC of 0.938 (95% CI: 0.886– 0.991) for predicting mortality risk. Conclusion: These findings underscore the potential of sFlt-1 as a valuable biomarker for clinical decision-making in managing COVID-19 patients. Future studies should focus on the clinical application of sFlt-1 and explore its underlying mechanisms to enhance patient management strategies.
- Open Access
- 1 June 2024
- Published by Taylor & Francis in Journal of Inflammation Research
- Vol. ume 17, 3879-3891
sTREM-1 as a Predictive Biomarker for Disease Severity and Prognosis in COVID-19 Patients
Background: Research on biomarkers associated with the severity and adverse prognosis of COVID-19 can be beneficial for improving patient outcomes. However, there is limited research on the role of soluble TREM-1 (sTREM-1) in predicting the severity and prognosis of COVID-19 patients. Methods: A total of 115 COVID-19 patients admitted to the emergency department of Beijing Youan Hospital from February to May 2023 were included in the study. Demographic information, laboratory measurements, and blood samples for sTREM-1 levels were collected upon admission. Results: Our study found that sTREM-1 levels in the plasma of COVID-19 patients increased with the severity of the disease (moderate vs mild, p=0.0013; severe vs moderate, p=0.0195). sTREM-1 had good predictive value for disease severity and 28-day mortality (area under the ROC curve was 0.762 and 0.805, respectively). sTREM-1 also exhibited significant correlations with age, body temperature, respiratory rate, PaO2/FiO2, PCT, CRP, and CAR. Ultimately, through multivariate logistic regression analysis, we determined that sTREM-1 (OR 1.008, 95% CI: 1.002– 1.013, p=0.005), HGB (OR 0.966, 95% CI: 0.935– 0.998, p=0.036), D-dimer (OR 1.001, 95% CI: 1.000– 1.001, p=0.009), and CAR (OR 1.761, 95% CI: 1.154– 2.688, p=0.009) were independent predictors of 28-day mortality in COVID-19 patients. The combination of these four markers yielded a strong predictive value for 28-day mortality in COVID-19 cases with an AUC of 0.919 (95% CI: 0.857 − 0.981). Conclusion: sTREM-1 demonstrated good predictive value for disease severity and 28-day mortality, serving as an independent prognostic factor for adverse patient outcomes. In the future, we anticipate conducting large-scale multicenter studies to validate our research findings.
- 1 June 2024
- Published by Taylor & Francis in Journal of Inflammation Research
- Vol. ume 17, 3879-3891
Open AccesssTREM-1 as a Predictive Biomarker for Disease Severity and Prognosis in COVID-19 Patients
Background: Research on biomarkers associated with the severity and adverse prognosis of COVID-19 can be beneficial for improving patient outcomes. However, there is limited research on the role of soluble TREM-1 (sTREM-1) in predicting the severity and prognosis of COVID-19 patients. Methods: A total of 115 COVID-19 patients admitted to the emergency department of Beijing Youan Hospital from February to May 2023 were included in the study. Demographic information, laboratory measurements, and blood samples for sTREM-1 levels were collected upon admission. Results: Our study found that sTREM-1 levels in the plasma of COVID-19 patients increased with the severity of the disease (moderate vs mild, p=0.0013; severe vs moderate, p=0.0195). sTREM-1 had good predictive value for disease severity and 28-day mortality (area under the ROC curve was 0.762 and 0.805, respectively). sTREM-1 also exhibited significant correlations with age, body temperature, respiratory rate, PaO2/FiO2, PCT, CRP, and CAR. Ultimately, through multivariate logistic regression analysis, we determined that sTREM-1 (OR 1.008, 95% CI: 1.002– 1.013, p=0.005), HGB (OR 0.966, 95% CI: 0.935– 0.998, p=0.036), D-dimer (OR 1.001, 95% CI: 1.000– 1.001, p=0.009), and CAR (OR 1.761, 95% CI: 1.154– 2.688, p=0.009) were independent predictors of 28-day mortality in COVID-19 patients. The combination of these four markers yielded a strong predictive value for 28-day mortality in COVID-19 cases with an AUC of 0.919 (95% CI: 0.857 − 0.981). Conclusion: sTREM-1 demonstrated good predictive value for disease severity and 28-day mortality, serving as an independent prognostic factor for adverse patient outcomes. In the future, we anticipate conducting large-scale multicenter studies to validate our research findings.
- Open Access
- 26 April 2024
- Published by Springer Nature in Virology Journal
- Vol. 21 (1) , 1-15
Presepsin as a prognostic biomarker in COVID-19 patients: combining clinical scoring systems and laboratory inflammatory markers for outcome prediction
Background: There is still limited research on the prognostic value of Presepsin as a biomarker for predicting the outcome of COVID-19 patients. Additionally, research on the combined predictive value of Presepsin with clinical scoring systems and inflammation markers for disease prognosis is lacking. Methods: A total of 226 COVID-19 patients admitted to Beijing Youan Hospital’s emergency department from May to November 2022 were screened. Demographic information, laboratory measurements, and blood samples for Presepsin levels were collected upon admission. The predictive value of Presepsin, clinical scoring systems, and inflammation markers for 28-day mortality was analyzed. Results: A total of 190 patients were analyzed, 83 (43.7%) were mild, 61 (32.1%) were moderate, and 46 (24.2%) were severe/critically ill. 23 (12.1%) patients died within 28 days. The Presepsin levels in severe/critical patients were significantly higher compared to moderate and mild patients (p < 0.001). Presepsin showed significant predictive value for 28-day mortality in COVID-19 patients, with an area under the ROC curve of 0.828 (95% CI: 0.737–0.920). Clinical scoring systems and inflammation markers also played a significant role in predicting 28-day outcomes. After Cox regression adjustment, Presepsin, qSOFA, NEWS2, PSI, CURB-65, CRP, NLR, CAR, and LCR were identified as independent predictors of 28-day mortality in COVID-19 patients (all p-values < 0.05). Combining Presepsin with clinical scoring systems and inflammation markers further enhanced the predictive value for patient prognosis. Conclusion: Presepsin is a favorable indicator for the prognosis of COVID-19 patients, and its combination with clinical scoring systems and inflammation markers improved prognostic assessment.
- 26 April 2024
- Published by Springer Nature in Virology Journal
- Vol. 21 (1) , 1-15
Open AccessPresepsin as a prognostic biomarker in COVID-19 patients: combining clinical scoring systems and laboratory inflammatory markers for outcome prediction
Background: There is still limited research on the prognostic value of Presepsin as a biomarker for predicting the outcome of COVID-19 patients. Additionally, research on the combined predictive value of Presepsin with clinical scoring systems and inflammation markers for disease prognosis is lacking. Methods: A total of 226 COVID-19 patients admitted to Beijing Youan Hospital’s emergency department from May to November 2022 were screened. Demographic information, laboratory measurements, and blood samples for Presepsin levels were collected upon admission. The predictive value of Presepsin, clinical scoring systems, and inflammation markers for 28-day mortality was analyzed. Results: A total of 190 patients were analyzed, 83 (43.7%) were mild, 61 (32.1%) were moderate, and 46 (24.2%) were severe/critically ill. 23 (12.1%) patients died within 28 days. The Presepsin levels in severe/critical patients were significantly higher compared to moderate and mild patients (p < 0.001). Presepsin showed significant predictive value for 28-day mortality in COVID-19 patients, with an area under the ROC curve of 0.828 (95% CI: 0.737–0.920). Clinical scoring systems and inflammation markers also played a significant role in predicting 28-day outcomes. After Cox regression adjustment, Presepsin, qSOFA, NEWS2, PSI, CURB-65, CRP, NLR, CAR, and LCR were identified as independent predictors of 28-day mortality in COVID-19 patients (all p-values < 0.05). Combining Presepsin with clinical scoring systems and inflammation markers further enhanced the predictive value for patient prognosis. Conclusion: Presepsin is a favorable indicator for the prognosis of COVID-19 patients, and its combination with clinical scoring systems and inflammation markers improved prognostic assessment.
- Open Access
- 20 November 2023
- Published by Wiley in Emergency Medicine International
- Vol. 2023, 1-14
Research Progress on the Mechanism and Management of Septic Cardiomyopathy: A Comprehensive Review
Sepsis is defined as a kind of life-threatening organ dysfunction due to a dysregulated host immune response to infection and is a leading cause of mortality in the intensive care unit. Sepsis-induced myocardial dysfunction, also called septic cardiomyopathy, is a common and serious complication in patients with sepsis, which may indicate a bad prognosis. Although efforts have been made to uncover the pathophysiology of septic cardiomyopathy, a number of uncertainties remain. This article sought to review available literature to summarize the existing knowledge on current diagnostic tools and biomarkers, pathogenesis, and treatments for septic cardiomyopathy.
- 20 November 2023
- Published by Wiley in Emergency Medicine International
- Vol. 2023, 1-14
Open AccessResearch Progress on the Mechanism and Management of Septic Cardiomyopathy: A Comprehensive Review
Sepsis is defined as a kind of life-threatening organ dysfunction due to a dysregulated host immune response to infection and is a leading cause of mortality in the intensive care unit. Sepsis-induced myocardial dysfunction, also called septic cardiomyopathy, is a common and serious complication in patients with sepsis, which may indicate a bad prognosis. Although efforts have been made to uncover the pathophysiology of septic cardiomyopathy, a number of uncertainties remain. This article sought to review available literature to summarize the existing knowledge on current diagnostic tools and biomarkers, pathogenesis, and treatments for septic cardiomyopathy.